Literature DB >> 791563

Influence of cannabidiol on secobarbital effects and plasma kinetics.

W S Dalton, R Martz, B E Rodda, L Lemberger, R B Forney.   

Abstract

To investigate the possible metabolic interaction between cannabidiol (CBD) and secobarbital, 6 male volunteers received 150 mg/70 kg sodium secobarbital orally immediately after smoking a marihuana cigarette prepared to deliver 0, 150, or 500 mug/kg CBD. The study was performed in a double-blind manner with each of the three treatments being assigned to every subject. Clinical effects and plasma secobarbital concentrations were recorded at periodic intervals. CBD did not alter the summary parameters which describe the secobarbital plasma concentration time curve. Secobarbital half-life, peak concentration, time of peak concentration, and area under the curve were unchanged by the coadministration of CBD. Clinical effects of secobarbital were also unaltered by CBD pretreatment. Thus at the doses administered, CBD does not appear to inhibit secobarbital metabolism in man.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 791563     DOI: 10.1002/cpt1976206695

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

Review 1.  Clinical pharmacokinetics of hypnotics.

Authors:  D D Breimer
Journal:  Clin Pharmacokinet       Date:  1977 Mar-Apr       Impact factor: 6.447

Review 2.  Role of tobacco smoking in pharmacokinetics.

Authors:  W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1978-02

3.  [Perdormal kinetics].

Authors:  G L Dadisch
Journal:  Z Rechtsmed       Date:  1983

4.  Development of tolerance to the prolongation of hexobarbitone sleeping time caused by cannabidiol.

Authors:  H K Borys; G B Ingall; R Karler
Journal:  Br J Pharmacol       Date:  1979-09       Impact factor: 8.739

5.  Comparing single and cumulative dosing procedures in human triazolam discriminators.

Authors:  B J Smith; W K Bickel
Journal:  J Exp Anal Behav       Date:  1999-05       Impact factor: 2.468

6.  Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man.

Authors:  C A Hunt; R T Jones; R I Herning; J Bachman
Journal:  J Pharmacokinet Biopharm       Date:  1981-06

7.  A New Data Repository for Pharmacokinetic Natural Product-Drug Interactions: From Chemical Characterization to Clinical Studies.

Authors:  Caroline Birer-Williams; Brandon T Gufford; Eric Chou; Marijanel Alilio; Sidney VanAlstine; Rachael E Morley; Jeannine S McCune; Mary F Paine; Richard D Boyce
Journal:  Drug Metab Dispos       Date:  2020-06-29       Impact factor: 3.922

Review 8.  Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy.

Authors:  István Ujváry; Lumír Hanuš
Journal:  Cannabis Cannabinoid Res       Date:  2016-03-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.